The Centre consists of a number of inter-related research teams covering a range of disciplines.
The oncology group aims to develop new treatments to target cancer by focusing at the interface between laboratory and clinical research. The generation of anti-glycan mAbs and their ability to induce rapid tumour cell death makes them ideal cancer therapeutics. Members of the group researching infectious disease agents are seeking unique approaches to combat pathogenic strains of community associated MRSA by utilising therapeutic, toxin-neutralising mAbs.
Alongside the investment from the University, oncology research in the Centre is supported by: